Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells

Pharmaceutical Research

Volumn 31, Issue 1, 2014, Pages 86-96

  Li, Qing ^a,b   Shu, Yan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

doxorubicin; endocytosis; lung cancer; phosphodiesterase type 5 (PDE5) inhibitor; trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEXTRAN; DIPYRIDAMOLE; DOXORUBICIN; FERRIC UPTAKE REGULATOR; OXALIPLATIN; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SODIUM CHLORIDE; TRASTUZUMAB; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; MULTIPLE CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOCYTOSIS; HELA CELLS; HEP G2 CELLS; HUMANS; LUNG NEOPLASMS; MCF-7 CELLS; MICE; MICE, NUDE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84891628287     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1134-0     Document Type: Article

References (47)

1. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, et al. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer. 2005;104:1968-74. (Pubitemid 41513182)
2. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, et al. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer. 2005;104:1281-7. (Pubitemid 41278964)
3. Matsukado K, Sugita M, Black KL. Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res. 1998;792:10-5. (Pubitemid 28261163)
4. Emerich DF, Dean RL, Snodgrass P, Lafreniere D, Agostino M, Wiens T, et al. Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther. 2001;296:632-41. (Pubitemid 32112494)
5. Nakano S, Matsukado K, Black KL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res. 1996;56:4027-31. (Pubitemid 26284755)
6. Yin D, Wang X, Konda BM, Ong JM, Hu J, Sacapano MR, et al. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. Clin Cancer Res. 2008;14:4002-9.
7. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 2008;1230:290-302.
8. Hu J, Ljubimova JY, Inoue S, Konda B, Patil R, Ding H, et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One. 2010;5:e10108.
9. Ningaraj NS, Rao M, Hashizume K, Asotra K, Black KL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther. 2002;301:838-51. (Pubitemid 34595072)
10. Ningaraj NS, Rao MK, Black KL. Adenosine 5′-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res. 2003;63:8899-911. (Pubitemid 38064070)
11. Hu J, Yuan X, Ko MK, Yin D, Sacapano MR, Wang X, et al. Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model. Mol Cancer. 2007;6:22. (Pubitemid 46488207)
12. Emerich DF, Snodgrass P, Dean RL, Lafreniere D, Agostino M, Wiens T, et al. Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy. J Pharmacol Exp Ther. 2001;296:623-31. (Pubitemid 32112493)
13. Inamuraand T, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab. 1994;14:862-70. (Pubitemid 24266539)
14. Black KL, Yin D, Konda BM, Wang X, Hu J, Ko MK, et al. Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models. Brain Res. 2008;1227:198-206.
15. Corbinand JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999;274:13729-32. (Pubitemid 29228003)
16. Corbin JD, Beasley A, Blount MA, Francis SH. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int. 2004;45:859-63. (Pubitemid 39108058)
17. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol. 1995;269:H473-9.
18. Barberi-Heyob M, Griffon G, Merlin JL, Weber B. Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole. Cancer Chemother Pharmacol. 1993;33:163-70. (Pubitemid 23325419)
19. Rodrigues M, Barbosa Jr F, Perussi JR. Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells in vitro. Braz J Med Biol Res. 2004;37:591-9. (Pubitemid 38618556)
20. Jekunen A, Vick J, Sanga R, Chan TC, Howell SB. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res. 1992;52:3566-71.
21. Gerlierand D, Thomasset N. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods. 1986;94:57-63. (Pubitemid 17186343)
22. Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2009;135:259-67.
23. Yumoto R, Nishikawa H, Okamoto M, Katayama H, Nagai J, Takano M. Clathrin-mediated endocytosis of FITC-albumin in alveolar type II epithelial cell line RLE-6TN. Am J Physiol Lung Cell Mol Physiol. 2006;290:L946-55. (Pubitemid 43725056)
24. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007;99:694-705. (Pubitemid 47073531)
25. Michalke B. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. J Trace Elem Med Biol. 2010;24:69-77.
26. Olszewskiand U, Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem. 2010;10:293-301.
27. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573-84. (Pubitemid 47106628)
28. Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer. 1995;71:676-83.
29. Mercerand J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009;11:510-20.
30. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther. 2003;2:479-88.
31. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res. 2002;8:904-12. (Pubitemid 34742124)
32. Loftsson T, Konradsdottir F, Masson M. Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes. Pharmazie. 2006;61:83-9.
33. Schinkeland AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55:3-29. (Pubitemid 36078452)
34. Danieland H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 2004;447:610-8. (Pubitemid 38241445)
35. Hagenbuchand B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447:653-65. (Pubitemid 38241451)
36. Koepselland H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004;447:666-76. (Pubitemid 38241452)
37. Parkar NS, Akpa BS, Nitsche LC, Wedgewood LE, Place AT, Sverdlov MS, et al. Vesicle formation and endocytosis: function, machinery, mechanisms, and modeling. Antioxid Redox Signal. 2009;11:1301-12.
38. Beltingand M, Wittrup A. Developments in macromolecular drug delivery. Methods Mol Biol. 2009;480:1-10.
39. Zhang Q, Hong M, Duan P, Pan Z, Ma J, You G. Organic anion transporter OAT1 undergoes constitutive and protein kinase C-regulated trafficking through a dynamin- and clathrin-dependent pathway. J Biol Chem. 2008;283:32570-9.
40. Jiang W, Prokopenko O, Wong L, Inouye M, Mirochnitchenko O. IRIP, a new ischemia/reperfusion-inducible protein that participates in the regulation of transporter activity. Mol Cell Biol. 2005;25:6496-508. (Pubitemid 41023225)
41. Kroiss M, Leyerer M, Gorboulev V, Kuhlkamp T, Kipp H, Koepsell H. Transporter regulator RS1 (RSC1A1) coats the trans-Golgi network and migrates into the nucleus. Am J Physiol Renal Physiol. 2006;291:F1201-12. (Pubitemid 44887233)
42. Filatova A, Leyerer M, Gorboulev V, Chintalapati C, Reinders Y, Muller TD, et al. Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location. Traffic. 2009;10:1599-618.
43. Korn T, Kuhlkamp T, Track C, Schatz I, Baumgarten K, Gorboulev V, et al. The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells. J Biol Chem. 2001;276:45330-40.
44. Zhuand B, Strada SJ. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem. 2007;7:437-54. (Pubitemid 46358655)
45. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60:3338-42. (Pubitemid 30482142)
46. Eguchi K, Nakanishi S, Takagi H, Taoufiq Z, Takahashi T. Maturation of a PKG-dependent retrograde mechanism for exoendocytic coupling of synaptic vesicles. Neuron. 2012;74:517-29.
47. Scrima M, De Marco C, De Vita F, Fabiani F, Franco R, Pirozzi G, et al. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. Am J Pathol. 2012;180:1202-14.